92 results on '"Kostakoglu L"'
Search Results
2. Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients
- Author
-
Eertink, J.J., Burggraaff, C.N., Heymans, M.W., Dührsen, U., Hüttmann, A., Schmitz, C., Müller, S., Lugtenburg, P.J., Barrington, S.F., Mikhaeel, N.G., Carr, R., Czibor, S., Györke, T., Ceriani, L., Zucca, E., Hutchings, M., Kostakoglu, L., Loft, A., Fanti, S., Wiegers, S.E., Pieplenbosch, S., Boellaard, R., Hoekstra, O.S., Zijlstra, J.M., and de Vet, H.C.W.
- Published
- 2021
- Full Text
- View/download PDF
3. Additional file 1 of Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments
- Author
-
Jemaa, S., Paulson, J. N., Hutchings, M., Kostakoglu, L., Trotman, J., Tracy, S., de Crespigny, A., Carano, R. A. D., El-Galaly, T. C., Nielsen, T. G., and Bengtsson, T.
- Abstract
Additional file 1.
- Published
- 2022
- Full Text
- View/download PDF
4. Does interim PET increase the value of ABVD in advanced-stage Hodgkin lymphoma?
- Author
-
Gallamini, A. and Kostakoglu, L.
- Published
- 2015
- Full Text
- View/download PDF
5. S1598 BASELINE TOTAL METABOLIC TUMOR VOLUME IS HIGHLY PROGNOSTIC FOR REFRACTORINESS TO IMMUNOCHEMOTHERAPY IN DLBCL: AN ANALYSIS OF THE PHASE 3 GOYA TRIAL
- Author
-
Trněný, M., primary, Canales Ruiz, I., additional, Martelli, M., additional, Sehn, L. H., additional, Vitolo, U., additional, Brown, H., additional, Nielsen, T., additional, Sellam, G., additional, and Kostakoglu, L., additional
- Published
- 2019
- Full Text
- View/download PDF
6. ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using F-18-FMISO PET and MRI
- Author
-
Gerstner, ER, Zhang, Z, Fink, JR, Muzi, M, Hanna, L, Greco, E, Prah, M, Schmainda, KM, Mintz, A, Kostakoglu, L, Eikman, EA, Ellingson, BM, Ratai, E-M, Sorensen, AG, Barboriak, DP, Mankoff, DA, and Grp, ACRINT
- Published
- 2016
7. Cerebral [18 F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy
- Author
-
Dickstein, D L, primary, Pullman, M Y, additional, Fernandez, C, additional, Short, J A, additional, Kostakoglu, L, additional, Knesaurek, K, additional, Soleimani, L, additional, Jordan, B D, additional, Gordon, W A, additional, Dams-O'Connor, K, additional, Delman, B N, additional, Wong, E, additional, Tang, C Y, additional, DeKosky, S T, additional, Stone, J R, additional, Cantu, R C, additional, Sano, M, additional, Hof, P R, additional, and Gandy, S, additional
- Published
- 2016
- Full Text
- View/download PDF
8. Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury
- Author
-
Mitsis, E M, primary, Riggio, S, additional, Kostakoglu, L, additional, Dickstein, D L, additional, Machac, J, additional, Delman, B, additional, Goldstein, M, additional, Jennings, D, additional, D’Antonio, E, additional, Martin, J, additional, Naidich, T P, additional, Aloysi, A, additional, Fernandez, C, additional, Seibyl, J, additional, DeKosky, S T, additional, Elder, G A, additional, Marek, K, additional, Gordon, W, additional, Hof, P R, additional, Sano, M, additional, and Gandy, S, additional
- Published
- 2014
- Full Text
- View/download PDF
9. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale
- Author
-
Gallamini, A., primary, Barrington, S. F., additional, Biggi, A., additional, Chauvie, S., additional, Kostakoglu, L., additional, Gregianin, M., additional, Meignan, M., additional, Mikhaeel, G. N., additional, Loft, A., additional, Zaucha, J. M., additional, Seymour, J. F., additional, Hofman, M. S., additional, Rigacci, L., additional, Pulsoni, A., additional, Coleman, M., additional, Dann, E. J., additional, Trentin, L., additional, Casasnovas, O., additional, Rusconi, C., additional, Brice, P., additional, Bolis, S., additional, Viviani, S., additional, Salvi, F., additional, Luminari, S., additional, and Hutchings, M., additional
- Published
- 2014
- Full Text
- View/download PDF
10. Positron emission tomography/computed tomography surveillance in patients with lymphoma: a fox hunt?
- Author
-
Gallamini, A., primary and Kostakoglu, L., additional
- Published
- 2012
- Full Text
- View/download PDF
11. OT2-05-03: ACRIN 6688 Phase II Study of Fluorine-18 3′-Deoxy-3′ Fluorothymidine (FLT) in Invasive Breast Cancer.
- Author
-
Jolles, PJ, primary, Kostakoglu, L, additional, Bear, HD, additional, Idowu, MO, additional, Kurdziel, K, additional, Shankar, L, additional, Mankoff, DA, additional, Duan, F, additional, and L'Heureux, DZ, additional
- Published
- 2011
- Full Text
- View/download PDF
12. The Significance and Management of Incidental [18F]Fluorodeoxyglucose–Positron-Emission Tomography Uptake in the Thyroid Gland in Patients with Cancer
- Author
-
Eloy, J.A., primary, Brett, E.M., additional, Fatterpekar, G.M., additional, Kostakoglu, L., additional, Som, P.M., additional, Desai, S.C., additional, and Genden, E.M., additional
- Published
- 2009
- Full Text
- View/download PDF
13. High Uptake in Schneiderian Papillomas of the Maxillary Sinus on Positron-Emission Tomography Using Fluorodeoxyglucose
- Author
-
Lin, F.Y., primary, Genden, E.M., additional, Lawson, W.L., additional, Som, P., additional, and Kostakoglu, L., additional
- Published
- 2008
- Full Text
- View/download PDF
14. Comparison of technetium-99m-MIBI and thallium-201-chloride uptake in primary thyroid lymphoma
- Author
-
Andrew Scott, Kostakoglu L, Brien Jp, O., Dj, Straus, Hm, Abdel-Dayem, and Sm, Larson
- Subjects
Technetium Tc 99m Sestamibi ,Thallium Radioisotopes ,Lymphoma, B-Cell ,Nitriles ,Humans ,Female ,Lymphoma, Large B-Cell, Diffuse ,Organotechnetium Compounds ,Thyroid Neoplasms ,Middle Aged ,Radionuclide Imaging - Abstract
A case of primary thyroid lymphoma demonstrating uptake of 99mTc-hexakis-2-methoxy isobutyl isonitrile (MIBI) is presented. The 99mTc-MIBI image more clearly delineated the extent of tumor as demonstrated on CT compared to 201Tl-chloride and [99mTc]pertechnetate images. Following two courses of chemotherapy, repeat radionuclide studies and CT scan showed complete resolution of the thyroid tumor. Technetium-99m-MIBI may be useful in the assessment of disease activity and monitoring response to treatment in patients with lymphoma.
- Published
- 1992
15. Phase I Radioimmunotherapy Trial with Iodine-131-CC49 in Metastatic Colon Carcinoma.
- Author
-
Divgi, C. R., Scott, A. M., Dantis, L., Capiteffi, P., Siler, K., Hilton, S., Finn, R. D., Kemeny, N., Kelsen, D., Kostakoglu, L., Schiom, J., and Larson, S. M.
- Published
- 1995
16. Cerebral [18 F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy.
- Author
-
Dickstein, D L, Pullman, M Y, Fernandez, C, Short, J A, Kostakoglu, L, Knesaurek, K, Soleimani, L, Jordan, B D, Gordon, W A, Dams-O'Connor, K, Delman, B N, Wong, E, Tang, C Y, DeKosky, S T, Stone, J R, Cantu, R C, Sano, M, Hof, P R, and Gandy, S
- Published
- 2016
- Full Text
- View/download PDF
17. Extraperitoneal urine leak after renal transplantation: the role of radionuclide imaging and the value of accompanying SPECT/CT - a case report
- Author
-
Kostakoglu Lale, Heiba Sherif, Son Hongju, and Machac Josef
- Subjects
Medical technology ,R855-855.5 - Abstract
Abstract Background The differentiation of the nature of a fluid collection as a complication of kidney transplantation is important for management and treatment planning. Early and delayed radionuclide renography can play an important role in the evaluation of a urine leak. However, it is sometimes limited in the evaluation of the exact location and extent of a urine leak. Case Presentation A 71-year-old male who had sudden anuria, scrotal swelling and elevated creatinine level after cadaveric renal transplantation performed Tc-99 m MAG3 renography to evaluate the renal function, followed by an ultrasound which was unremarkable. An extensive urine leak was evident on the planar images. However, an exact location of the urine leak was unknown. Accompanying SPECT/CT images confirmed a urine leak extending from the lower aspect of the transplant kidney to the floor of the pelvic cavity, presacral region and the scrotum via right inguinal canal as well as to the right abdominal wall. Conclusions Renal scintigraphy is very useful to detect a urine leak after renal transplantation. However, planar imaging is sometimes limited in evaluating the anatomical location and extent of a urine leak accurately. In that case accompanying SPECT/CT images are very helpful and valuable to evaluate the anatomical relationships exactly.
- Published
- 2010
- Full Text
- View/download PDF
18. Optimal timing and criteria of interim PET in DLBCL: A comparative study of 1692 patients
- Author
-
Sanne E Wiegers, Stefan P. Müller, N. G. Mikhaeel, Robert Carr, Luca Ceriani, Annika Loft, Tamás Györke, Martin Hutchings, Jakoba J Eertink, Pieternella J. Lugtenburg, Emanuele Zucca, Ulrich Dührsen, Ronald Boellaard, Christine Schmitz, Simone Pieplenbosch, Andreas Hüttmann, H.C.W. de Vet, Sally F. Barrington, S. Czibor, J. M. Zijlstra, L. Kostakoglu, Coreline N. Burggraaff, Otto S. Hoekstra, Stefano Fanti, Martijn W. Heymans, Eertink JJ, Burggraaff CN, Heymans MW, Dührsen U, Hüttmann A, Schmitz C, Müller S, Lugtenburg PJ, Barrington SF, Mikhaeel NG, Carr R, Czibor S, Györke T, Ceriani L, Zucca E, Hutchings M, Kostakoglu L, Loft A, Fanti S, Wiegers SE, Pieplenbosch S, Boellaard R, Hoekstra OS, Zijlstra JM, de Vet HCW., Hematology, VU University medical center, Internal medicine, Epidemiology and Data Science, APH - Methodology, APH - Personalized Medicine, Radiology and nuclear medicine, Amsterdam Neuroscience - Brain Imaging, CCA - Imaging and biomarkers, and CCA - Cancer Treatment and quality of life
- Subjects
Oncology ,medicine.medical_specialty ,Medizin ,Context (language use) ,Standardized uptake value ,DLBCL, interim PET ,030218 nuclear medicine & medical imaging ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,International Prognostic Index ,Randomized controlled trial ,Fluorodeoxyglucose F18 ,law ,Prednisone ,Internal medicine ,Humans ,Medicine ,Lymphoid Neoplasia ,business.industry ,Proportional hazards model ,Hazard ratio ,Hematology ,Prognosis ,Vincristine ,Positron-Emission Tomography ,030220 oncology & carcinogenesis ,Rituximab ,Lymphoma, Large B-Cell, Diffuse ,business ,medicine.drug - Abstract
Interim 18F-fluorodeoxyglucose positron emission tomography (Interim- 18F-FDG-PET,hereafter I-PET) has the potential to guide treatment of patients with diffuse large B-celllymphoma (DLBCL) if the prognostic value is known. The aim of this study was to determinethe optimal timing and response criteria for evaluating prognosis with I-PET in DLBCL.Individual patient data from 1692 patients with de novo DLBCL were combined and scans were harmonized. I-PET was performed at various time points during treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. Scans were interpreted using the Deauville score (DS) and change in maximum standardized uptake value (DSUVmax ). Multilevel Cox proportional hazards models corrected for International Prognostic Index (IPI) score were used to study the effects oftiming and response criteria on 2-year progression-free survival (PFS). I-PET after 2 cycles (I-PET2) and I-PET4 significantly discriminated good responders from poor responders, with the highest hazard ratios (HRs) for I-PET4. Multivariable HRs for a PET-positive result at I-PET2 and I-PET4 were 1.71 and 2.95 using DS4-5, 4.91 and 6.20 using DS5, and 2.93 and 4.65 using DSUVmax , respectively. DSUVmax identified a larger proportion of poor respondersthan DS5 did. For all criteria, the negative predictive value was >80%, and positivepredictive values ranged from 30% to 70% at I-PET2 and I-PET4. Unlike I-PET1, I-PET3discriminated good responders from poor responders using DS4-5 and DS5 thresholds (HRs,2.94 and 4.67, respectively). I-PET2 and I-PET4 predict good response equally during R-CHOPtherapy in DLBCL. Optimal timing and response criteria depend on the clinical context. Goodresponse at I-PET2 is suggested for de-escalation trials, and poor response using DSUVmax atI-PET4 is suggested for randomized trials that are evaluating new therapies
- Published
- 2021
19. Supporting Imaging at the Highest Level: Janet Eary Talks with Lale Kostakoglu About NCI Leadership in Advancing Imaging.
- Author
-
Eary J and Kostakoglu L
- Subjects
- United States, Humans, History, 21st Century, Diagnostic Imaging, History, 20th Century, Leadership, National Cancer Institute (U.S.)
- Published
- 2024
- Full Text
- View/download PDF
20. A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials.
- Author
-
Kostakoglu L, Martelli M, Sehn LH, Davies A, Trněný M, Herold M, Vitolo U, Hiddemann W, Trotman J, Knapp A, Mattiello F, Nielsen TG, Sahin D, Sellam G, Ward C, and Younes A
- Abstract
The Lugano 2014 criteria are the standard for response assessment in lymphoma. We compared the prognostic performance of Lugano 2014 and the more recently developed response evaluation criteria in lymphoma (RECIL 2017), which relies primarily on computed tomography and uses unidimensional measurements, in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) from the phase III GOYA and GALLIUM trials, respectively. Concordance between responses according to the Lugano 2014 and RECIL 2017 criteria was analyzed. Landmark analyses of progression-free survival (PFS) and overall survival (OS) by end of treatment (EOT) and end of induction (EOI) response status according to RECIL 2017 and Lugano 2014 criteria, and prognostic value of response at EOT/EOI were also compared. Overall, 1333 patients were included from GOYA and 502 from GALLIUM. Complete response (CR) status according to RECIL 2017 criteria showed high concordance with complete metabolic response (CMR) status by Lugano 2014 criteria in both GOYA (92.5%) and GALLIUM (92.4%). EOT and EOI CR/CMR status by both criteria was highly prognostic for PFS in GOYA (RECIL 2017 [CR]: hazard ratio [HR], 0.35 [95% confidence interval [CI] 0.26-0.46]; Lugano 2014 [CMR]: HR, 0.35 [95% CI 0.26-0.48]; both p < .0001) and GALLIUM (RECIL 2017 [CR]: HR, 0.35 [95% CI 0.23-0.53]; Lugano 2014 [CMR]: HR, 0.21 [95% CI 0.14-0.31]; both p < .0001). In conclusion, response categorization by RECIL 2017 is similar to that by Lugano 2014 criteria, with high concordance observed. Both were prognostic for PFS and OS., Competing Interests: Lale Kostakoglu is a consultant at F. Hoffmann‐La Roche Ltd, Genentech, Inc. and reports consulting and honoraria fees from F. Hoffmann‐La Roche Ltd. Maurizio Martelli has served on a consulting and advisory board and speaker's bureau for F. Hoffmann‐La Roche Ltd, Janssen, Novartis, Gilead Sciences and Sandoz; and reports travel, accommodations and other expenses from F. Hoffmann‐La Roche Ltd. Laurie H. Sehn reports research funding from F. Hoffmann‐La Roche Ltd and Genentech, Inc. and consulting and honoraria fees from F. Hoffmann‐La Roche Ltd, Genentech, Inc., AbbVie, Amgen, Apobiologix, Acerta, AstraZeneca, Celgene, Gilead Sciences, Janssen, Kite Pharma, Karyopharm, Lundbeck, Merck, MorphoSys, Seattle Genetics, Takeda, Teva, TG Therapeutics and Verastem. Andrew Davies reports research funding from F. Hoffmann‐La Roche Ltd and Genentech, Inc, AstraZeneca/Acerta Pharma, MSD and consulting and honoraria fees from F. Hoffmann‐La Roche Ltd, Genentech, Inc., AbbVie, Acerta/AstraZeneca, Celgene, Genmab, Gilead Sciences, Kite Pharma and Incyte. Marek Trněný reports honoraria and consulting fees from Janssen, Gilead Sciences, Bristol‐Meyers Squibb, Amgen, AbbVie, Takeda, F. Hoffmann‐La Roche Ltd, MorphoSys and Incyte; consulting for Celgene; and travel, accommodation and other expenses from AbbVie, Gilead Sciences, Bristol‐Meyers Squibb, Takeda, F. Hoffmann‐La Roche Ltd and Janssen. Michael Herold reports a consultancy/advisory role with Celgene, Gilead and F. Hoffmann‐La Roche Ltd and research funding from F. Hoffmann‐La Roche Ltd. Umberto Vitolo reports a consulting or advisory role for Janssen, Celgene, Juno Therapeutics, Kite Pharma, Genmab and Incyte; speaker's bureau fees from F. Hoffmann‐La Roche Ltd, Janssen, Celgene, Gilead Sciences, Servier and AbbVie; research funding from Celgene; and travel, accommodations or other expenses from Celgene, F. Hoffmann‐La Roche Ltd and AbbVie. Wolfgang Hiddemann reports honoraria from F. Hoffmann‐La Roche Ltd, Janssen, Gilead Sciences and Celgene; a consulting/advisory role for F. Hoffman‐La Roche Ltd, Janssen and Gilead Sciences; speakers’ bureau for F. Hoffmann‐La Roche Ltd, Janssen and Gilead Sciences; research funding from F. Hoffmann‐La Roche Ltd, Janssen and Bayer; and travel expenses/accommodation from F. Hoffmann‐La Roche Ltd, Janssen and Gilead Sciences. Judith Trotman reports research funding from F. Hoffmann‐La Roche Ltd, BMS, BeiGene, Pharmacyclics, Janssen and Cellectar. Andrea Knapp is employed by and has equity ownership interests in F. Hoffmann‐La Roche Ltd. Federico Mattiello is an employee of F. Hoffmann‐La Roche Ltd. Tina G. Nielsen is an employee and stockholder of F. Hoffmann‐La Roche Ltd. Deniz Sahin is an employee and stockholder of F. Hoffmann‐La Roche Ltd. Gila Sellam is an employee and stockholder of F. Hoffmann‐La Roche Ltd. Carol Ward is an employee and stockholder of F. Hoffmann‐La Roche Ltd. Anas Younes is employed by and has stock and other ownership interests in AstraZeneca; has received honoraria from Merck, F. Hoffmann‐La Roche Ltd, Takeda, Janssen, AbbVie, Curis and Epizyme; reports a consulting or advisory role with Bio‐Path Holdings Inc, Xynomic Pharma, Epizyme, F. Hoffmann‐La Roche Ltd, Celgene and HCM; has received research funding from Janssen, Curis, F. Hoffmann‐La Roche Ltd, Genentech, Inc., Merck, Bristol‐Myers Squibb, Syndax; and other relationship with AstraZeneca., (© 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
21. Defining Myeloma and Advancing Treatment Options: A Conversation Between S. Vincent Rajkumar and Lale Kostakoglu.
- Author
-
Rajkumar SV and Kostakoglu L
- Subjects
- Humans, Communication, Multiple Myeloma diagnostic imaging, Multiple Myeloma therapy
- Published
- 2023
- Full Text
- View/download PDF
22. A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma.
- Author
-
Thieblemont C, Chartier L, Dührsen U, Vitolo U, Barrington SF, Zaucha JM, Vercellino L, Gomes Silva M, Patrocinio-Carvalho I, Decazes P, Viailly PJ, Tilly H, Berriolo-Riedinger A, Casasnovas O, Hüttmann A, Ilyas H, Mikhaeel NG, Dunn J, Cottereau AS, Schmitz C, Kostakoglu L, Paulson JN, Nielsen T, and Meignan M
- Subjects
- Humans, Clinical Trials as Topic, Neoplasm Recurrence, Local, Tumor Burden, Lymphoma, Large B-Cell, Diffuse diagnosis, Lymphoma, Large B-Cell, Diffuse drug therapy
- Abstract
Aggressive large B-cell lymphoma (LBCL) has variable outcomes. Current prognostic tools use factors for risk stratification that inadequately identify patients at high risk of refractory disease or relapse before initial treatment. A model associating 2 risk factors, total metabolic tumor volume (TMTV) >220 cm3 (determined by fluorine-18 fluorodeoxyglucose positron emission tomography coupled with computed tomography) and performance status (PS) ≥2, identified as prognostic in 301 older patients in the REMARC trial (#NCT01122472), was validated in 2174 patients of all ages treated in 2 clinical trials, PETAL (Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas; N = 510) and GOYA (N = 1315), and in real-world clinics (N = 349) across Europe and the United States. Three risk categories, low (no factors), intermediate (1 risk factor), and high (2 risk factors), significantly discriminated outcome in most of the series. Patients with 2 risk factors had worse outcomes than patients with no risk factors in the PETAL, GOYA, and real-world series. Patients with intermediate risk also had significantly worse outcomes than patients with no risk factors. The TMTV/Eastern Cooperative Oncology Group-PS combination outperformed the International Prognostic Index with a positive C-index for progression-free survival and overall survival in most series. The combination of high TMTV > 220 cm3 and ECOG-PS ≥ 2 is a simple clinical model to identify aggressive LBCL risk categories before treatment. This combination addresses the unmet need to better predict before treatment initiation for aggressive LBCL the patients likely to benefit the most or not at all from therapy., (© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
23. Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study.
- Author
-
Barrington SF, Mir F, El-Galaly TC, Knapp A, Nielsen TG, Sahin D, Wenger M, Kostakoglu L, Trotman J, and Meignan M
- Subjects
- Fluorodeoxyglucose F18, Humans, Positron Emission Tomography Computed Tomography methods, Prognosis, Progression-Free Survival, Retrospective Studies, Gallium, Lymphoma, Follicular diagnostic imaging, Lymphoma, Follicular drug therapy
- Abstract
Complete metabolic response (CMR) on PET/CT was the sole independent predictor of overall survival in the PET substudy of the phase III GALLIUM trial (NCT01332968) in first-line treatment of high-tumor-burden follicular lymphoma. The aim of this analysis was to further investigate the outcome of patients not achieving CMR. Methods: Two international experts rereviewed PET/CT scans from patients failing to achieve CMR assessed by the Independent Review Committee masked otherwise to committee results. Metabolic response category and Deauville score were assigned. Progression-free survival (PFS) was investigator-assessed with contrast-enhanced CT. Kaplan-Meier methodology was used to estimate landmark PFS and time to next treatment from end of induction by Deauville score. Patients who experienced CT-based progressive disease at the end of induction were excluded. Results: Fifty-four patients were reviewed. Six had CMR, 37 had a partial metabolic response, 2 had no metabolic response, and 9 had progressive metabolic disease. Patients were reassigned to CMR because
18 F-FDG uptake was considered inflammatory ( n = 2), was considered incidental neoplasia ( n = 2), or was visually close to liver uptake but quantitatively lower ( n = 2). There was a trend for shorter PFS and time to next treatment for patients with a Deauville score of 5 than a score of 4. High-grade mesenteric uptake at the end of induction was common, occurring in 20 patients with non-CMR, 14 of whom achieved CMR at all other sites. Only 3 of 14 (21%) patients with mesenteric uptake as the only site of disease experienced progression or death within 24 mo, whereas 4 of 6 patients (67%) with mesenteric and additional sites of18 F-FDG-avid disease experienced progression or death within 24 mo. All patients with early progression had measurable disease on contrast-enhanced CT at18 F-FDG-avid sites at the end of induction. Conclusion: After induction immunochemotherapy, CMR was assigned after reassessment in some patients, in whom increased18 F-FDG uptake was considered due to inflammation or incidental neoplasia rather than to lymphoma. Quantitative assessment to confirm the visual impression of residual uptake in lesions is suggested. Isolated mesenteric18 F-FDG uptake is likely a common false-positive finding at the end of induction and does not warrant changes in clinical management or disease surveillance unless there is measurable disease on contrast-enhanced CT or clinical suspicion of active disease., (© 2022 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2022
- Full Text
- View/download PDF
24. Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study.
- Author
-
Kostakoglu L, Mattiello F, Martelli M, Sehn LH, Belada D, Ghiggi C, Chua N, González-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Bolen C, Knapp A, Sellam G, Nielsen T, Sahin D, Vitolo U, and Trněný M
- Subjects
- Glycolysis, Humans, Positron Emission Tomography Computed Tomography methods, Positron-Emission Tomography, Prognosis, Radiopharmaceuticals, Retrospective Studies, Tumor Burden, Fluorodeoxyglucose F18, Lymphoma, Large B-Cell, Diffuse
- Abstract
This retrospective analysis of the phase III GOYA study investigated the prognostic value of baseline metabolic tumor volume parameters and maximum standardized uptake values for overall and progression-free survival (PFS) in treatment-naïve diffuse large B-cell lymphoma. Baseline total metabolic tumor volume (determined for tumors >1 mL using a threshold of 1.5 times the mean liver standardized uptake value +2 standard deviations), total lesion glycolysis, and maximum standardized uptake value positron emission tomography data were dichotomized based on receiver operating characteristic analysis and divided into quartiles by baseline population distribution. Of 1,418 enrolled patients, 1,305 had a baseline positron emission tomography scan with detectable lesions. Optimal cut-offs were 366 cm3 for total metabolic tumor volume and 3,004 g for total lesion glycolysis. High total metabolic tumor volume and total lesion glycolysis predicted poorer PFS, with associations retained after adjustment for baseline and disease characteristics (high total metabolic tumor volume hazard ratio: 1.71, 95% confidence interval [CI]: 1.35- 2.18; total lesion glycolysis hazard ratio: 1.46; 95% CI: 1.15-1.86). Total metabolic tumor volume was prognostic for PFS in subgroups with International Prognostic Index scores 0-2 and 3-5, and those with different cell-of-origin subtypes. Maximum standardized uptake value had no prognostic value in this setting. High total metabolic tumor volume associated with high International Prognostic Index or non-germinal center B-cell classification identified the highest-risk cohort for unfavorable prognosis. In conclusion, baseline total metabolic tumor volume and total lesion glycolysis are independent predictors of PFS in patients with diffuse large B-cell lymphoma after first-line immunochemotherapy.
- Published
- 2022
- Full Text
- View/download PDF
25. Precision Medicine Clinical Trials: A Conversation Between Peter O'Dwyer and Lale Kostakoglu.
- Author
-
O'Dwyer PJ and Kostakoglu L
- Subjects
- Humans, Clinical Trials as Topic, Precision Medicine
- Published
- 2022
- Full Text
- View/download PDF
26. A prognostic model integrating PET-derived metrics and image texture analyses with clinical risk factors from GOYA.
- Author
-
Kostakoglu L, Dalmasso F, Berchialla P, Pierce LA, Vitolo U, Martelli M, Sehn LH, Trněný M, Nielsen TG, Bolen CR, Sahin D, Lee C, El-Galaly TC, Mattiello F, Kinahan PE, and Chauvie S
- Abstract
Image texture analysis (radiomics) uses radiographic images to quantify characteristics that may identify tumour heterogeneity and associated patient outcomes. Using fluoro-deoxy-glucose positron emission tomography/computed tomography (FDG-PET/CT)-derived data, including quantitative metrics, image texture analysis and other clinical risk factors, we aimed to develop a prognostic model that predicts survival in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) from GOYA (NCT01287741). Image texture features and clinical risk factors were combined into a random forest model and compared with the international prognostic index (IPI) for DLBCL based on progression-free survival (PFS) and overall survival (OS) predictions. Baseline FDG-PET scans were available for 1263 patients, 832 patients of these were cell-of-origin (COO)-evaluable. Patients were stratified by IPI or radiomics features plus clinical risk factors into low-, intermediate- and high-risk groups. The random forest model with COO subgroups identified a clearer high-risk population (45% 2-year PFS [95% confidence interval (CI) 40%-52%]; 65% 2-year OS [95% CI 59%-71%]) than the IPI (58% 2-year PFS [95% CI 50%-67%]; 69% 2-year OS [95% CI 62%-77%]). This study confirms that standard clinical risk factors can be combined with PET-derived image texture features to provide an improved prognostic model predicting survival in untreated DLBCL., Competing Interests: LK is a consultant at F. Hoffmann‐La Roche Ltd, Genentech, Inc., and reports travel, accommodations and other expenses to F. Hoffmann‐La Roche Ltd. LAP reports equity ownership in Precision Sensing LLC. UV reports a consulting or advisory role for Janssen, Celgene, Juno Therapeutics and Kite Pharma; speaker's bureau fees from F. Hoffmann‐La Roche Ltd, Janssen, Celgene, Gilead Sciences, Servier and AbbVie; research funding from Celgene; and travel, accommodations or other expenses from Celgene, F. Hoffmann‐La Roche Ltd and AbbVie. MM has served on a consulting and advisory board and speaker's bureau for F. Hoffmann‐La Roche Ltd, Janssen, Novartis, Gilead Sciences and Sandoz; and reports travel, accommodations and other expenses from F. Hoffmann‐La Roche Ltd. LHS reports research funding from F. Hoffmann‐La Roche Ltd and Genentech, Inc. and consulting and honoraria fees from F. Hoffmann‐La Roche Ltd, Genentech, Inc., AbbVie, Amgen, Apobiologix, Acerta, AstraZeneca, Celgene, Gilead Sciences, Janssen, Kite Pharma, Karyopharm, Lundbeck, Merck, MorphoSys, Seattle Genetics, Takeda, Teva, TG Therapeutics and Verastem. MT reports honoraria and consulting fees from Janssen, Gilead Sciences, Bristol‐Meyers Squibb, Amgen, AbbVie, Takeda, F. Hoffmann‐La Roche Ltd, MorphoSys and Incyte; consulting for Celgene; and travel, accommodation and other expenses from AbbVie, Gilead Sciences, Bristol‐Meyers Squibb, Takeda, F. Hoffmann‐La Roche Ltd and Janssen. TGN is an employee and stockholder of F. Hoffmann‐La Roche Ltd. CRB is an employee of Genentech, Inc. and stockholder of F. Hoffmann‐La Roche Ltd. DS is an employee and stockholder of F. Hoffmann‐La Roche Ltd. CL is an employee of Genentech, Inc. TCE‐G is a former employee of F. Hoffmann‐La Roche Ltd and reports speaker fees for AbbVie. FM is an employee of F. Hoffmann‐La Roche Ltd. SC reports research funding from F. Hoffmann‐La Roche Ltd. and honoraria fees from Sirtex Medical. FD, PB and PEK have declared no conflict of interest., (© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
27. End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA.
- Author
-
Kostakoglu L, Martelli M, Sehn LH, Belada D, Carella AM, Chua N, Gonzalez-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Knapp A, Mattiello F, Nielsen T, Sahin D, Sellam G, Oestergaard MZ, Vitolo U, and Trněný M
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Humans, Positron-Emission Tomography, Progression-Free Survival, Retrospective Studies, Lymphoma, Large B-Cell, Diffuse diagnostic imaging, Lymphoma, Large B-Cell, Diffuse drug therapy, Positron Emission Tomography Computed Tomography
- Abstract
GOYA was a randomized phase 3 study comparing obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) vs standard-of-care rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). This retrospective analysis of GOYA aimed to assess the association between progression-free survival (PFS) and overall survival (OS) with positron emission tomography (PET)-based complete response (CR) status. Overall, 1418 patients were randomly assigned to receive 8 21-day cycles of obinutuzumab (n = 706) or rituximab (n = 712) plus 6 or 8 cycles of CHOP. Patients received a mandatory fluoro-2-deoxy-d-glucose-PET/computed tomography scan at baseline and end of treatment. After a median follow-up of 29 months, the numbers of independent review committee-assessed PFS and OS events in the entire cohort were 416 (29.3%) and 252 (17.8%), respectively. End-of-treatment PET CR was highly prognostic for PFS and OS according to Lugano 2014 criteria (PFS: hazard ratio [HR], 0.26; 95% confidence interval [CI], 0.19-0.38; P < .0001; OS: HR, 0.12; 95% CI, 0.08-0.17; P < .0001), irrespective of international prognostic index score and cell of origin. In conclusion, the results from this prospectively acquired large cohort corroborated previously published data from smaller sample sizes showing that end-of-treatment PET CR is an independent predictor of PFS and OS and a promising prognostic marker in DLBCL. Long-term survival analysis confirmed the robustness of these data over time. Additional meta-analyses including other prospective studies are necessary to support the substitution of PET CR for PFS as an effective and practical surrogate end point. This trial was registered at www.clinicaltrials.gov as #NCT01287741., (© 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
28. The Future of Nuclear Medicine, Molecular Imaging, and Theranostics.
- Author
-
Weber WA, Czernin J, Anderson CJ, Badawi RD, Barthel H, Bengel F, Bodei L, Buvat I, DiCarli M, Graham MM, Grimm J, Herrmann K, Kostakoglu L, Lewis JS, Mankoff DA, Peterson TE, Schelbert H, Schöder H, Siegel BA, and Strauss HW
- Subjects
- Humans, Molecular Imaging, Nuclear Medicine, Therapeutics
- Published
- 2020
- Full Text
- View/download PDF
29. Convolutional Neural Networks for Automated PET/CT Detection of Diseased Lymph Node Burden in Patients with Lymphoma.
- Author
-
Weisman AJ, Kieler MW, Perlman SB, Hutchings M, Jeraj R, Kostakoglu L, and Bradshaw TJ
- Abstract
Purpose: To automatically detect lymph nodes involved in lymphoma on fluorine 18 (
18 F) fluorodeoxyglucose (FDG) PET/CT images using convolutional neural networks (CNNs)., Materials and Methods: In this retrospective study, baseline disease of 90 patients with lymphoma was segmented on18 F-FDG PET/CT images (acquired between 2005 and 2011) by a nuclear medicine physician. An ensemble of three-dimensional patch-based, multiresolution pathway CNNs was trained using fivefold cross-validation. Performance was assessed using the true-positive rate (TPR) and number of false-positive (FP) findings. CNN performance was compared with agreement between physicians by comparing the annotations of a second nuclear medicine physician to the first reader in 20 of the patients. Patient TPR was compared using Wilcoxon signed rank tests., Results: Across all 90 patients, a range of 0-61 nodes per patient was detected. At an average of four FP findings per patient, the method achieved a TPR of 85% (923 of 1087 nodes). Performance varied widely across patients (TPR range, 33%-100%; FP range, 0-21 findings). In the 20 patients labeled by both physicians, a range of 1-49 nodes per patient was detected and labeled. The second reader identified 96% (210 of 219) of nodes with an additional 3.7 per patient compared with the first reader. In the same 20 patients, the CNN achieved a 90% (197 of 219) TPR at 3.7 FP findings per patient., Conclusion: An ensemble of three-dimensional CNNs detected lymph nodes at a performance nearly comparable to differences between two physicians' annotations. This preliminary study is a first step toward automated PET/CT assessment for lymphoma.© RSNA, 2020., Competing Interests: Disclosures of Conflicts of Interest: A.J.W. Activities related to the present article: disclosed money paid to institution for research support by GE Healthcare. Activities not related to the present article: disclosed no relevant relationships. Other relationships: disclosed no relevant relationships. M.W.K. disclosed no relevant relationships. S.B.P. disclosed no relevant relationships. M.H. disclosed no relevant relationships. R.J. Activities related to the present article: disclosed grant money paid to institution by the National Cancer Institute, in part supported by the UW Carbone Cancer Center. Activities not related to the present article: disclosed no relevant relationships. Other relationships: disclosed patent issued by WARF and patent pending with AIQ Solutions. L.K. Activities related to the present article: disclosed no relevant relationships. Activities not related to the present article: disclosed money paid for consultancy by Roche, Genentech. Other relationships: disclosed no relevant relationships. T.J.B. Activities related to the present article: disclosed no relevant relationships. Activities not related to the present article: disclosed no relevant relationships. Other relationships: institution receives research support from GE Healthcare., (2020 by the Radiological Society of North America, Inc.)- Published
- 2020
- Full Text
- View/download PDF
30. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial.
- Author
-
Schöder H, Polley MC, Knopp MV, Hall N, Kostakoglu L, Zhang J, Higley HR, Kelloff G, Liu H, Zelenetz AD, Cheson BD, Wagner-Johnston N, Kahl BS, Friedberg JW, Hsi ED, Leonard JP, Schwartz LH, Wilson WH, and Bartlett NL
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cyclophosphamide administration & dosage, Etoposide administration & dosage, Female, Fluorine Radioisotopes, Fluorodeoxyglucose F18, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse mortality, Male, Middle Aged, Prednisone administration & dosage, Prognosis, Progression-Free Survival, Proportional Hazards Models, Prospective Studies, Radiopharmaceuticals, Rituximab administration & dosage, Vincristine administration & dosage, Young Adult, Lymphoma, Large B-Cell, Diffuse diagnostic imaging, Positron-Emission Tomography
- Abstract
As part of a randomized, prospective clinical trial in large cell lymphoma, we conducted serial fluorodeoxyglucose positron emission tomography (FDG-PET) at baseline, after 2 cycles of chemotherapy (interim PET [i-PET]), and at end of treatment (EoT) to identify biomarkers of response that are predictive of remission and survival. Scans were interpreted in a core laboratory by 2 imaging experts, using the visual Deauville 5-point scale (5-PS), and by calculating percent change in FDG uptake (change in standardized uptake value [ΔSUV]). Visual scores of 1 through 3 and ΔSUV ≥66% were prospectively defined as negative. Of 524 patients enrolled in the parent trial, 169 agreed to enroll in the PET substudy and 158 were eligible for final analysis. In this selected population, all had FDG-avid disease at baseline; by 5-PS, 55 (35%) remained positive on i-PET and 28 (18%) on EoT PET. Median ΔSUV on i-PET was 86.2%. With a median follow-up of 5 years, ΔSUV, as continuous variable, was associated with progression-free survival (PFS) (hazard ratio [HR] = 0.99; 95% confidence interval [CI], 0.97-1.00; P = .02) and overall survival (OS) (HR, 0.98; 95% CI, 0.97-0.99; P = .03). ΔSUV ≥66% was predictive of OS (HR, 0.31; 95% CI, 0.11-0.85; P = .02) but not PFS (HR, 0.47; 95% CI, 0.19-1.13; P = .09). Visual 5-PS on i-PET did not predict outcome. ΔSUV, but not visual analysis, on i-PET predicted OS in DLBCL, although the low number of events limited the statistical analysis. These data may help guide future clinical trials using PET response-adapted therapy. This trial was registered at www.clinicaltrials.gov as #NCT00118209.
- Published
- 2020
- Full Text
- View/download PDF
31. Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA.
- Author
-
Rutherford SC, Herold M, Hiddemann W, Kostakoglu L, Marcus R, Martelli M, Sehn LH, Trněný M, Trotman J, Vitolo U, Nielsen T, Mattiello F, Sahin D, Sellam G, and Martin P
- Subjects
- Biopsy, Fluorodeoxyglucose F18, Humans, Retrospective Studies, Bone Marrow, Gallium
- Abstract
The utility of posttreatment bone marrow biopsy (BMB) histology to confirm complete response (CR) in lymphoma clinical trials is in question. We retrospectively evaluated the impact of BMB on response assessment in immunochemotherapy-treated patients with previously untreated follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in the phase 3 Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM; NCT01332968) and A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA; NCT01287741) trials, respectively. Baseline BMB was performed in all patients, with repeat BMBs in patients with a CR by computed tomography (CT) at end of induction (EOI) and a positive BMB at baseline, to confirm response. Positron emission tomography imaging was also used in some patients to assess EOI response (Lugano 2014 criteria). Among patients with an EOI CR by CT in GALLIUM and GOYA, 2.8% and 4.1%, respectively, had a BMB-altered response. These results suggest that postinduction BMB histology has minimal impact on radiographically (CT)-defined responses in both FL and DLBCL patients. In GALLIUM and GOYA, respectively, 4.7% of FL patients and 7.1% of DLBCL patients had a repeat BMB result that altered response assessment when applying Lugano 2014 criteria, indicating that bone marrow evaluation appears to add little value to response assessment in FL; however, its evaluation may still have merit in DLBCL., (© 2020 by The American Society of Hematology.)
- Published
- 2020
- Full Text
- View/download PDF
32. Efficacy and Safety of High-Specific-Activity 131 I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma.
- Author
-
Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, Kostakoglu L, Serafini AN, Pampaloni MH, Jensen J, Armor T, Lin T, White T, Stambler N, Apfel S, DiPippo VA, Mahmood S, Wong V, and Jimenez C
- Subjects
- Adolescent, Adrenal Gland Neoplasms metabolism, Adrenal Gland Neoplasms pathology, Biomarkers, Tumor metabolism, Female, Humans, Male, Paraganglioma metabolism, Paraganglioma pathology, Pheochromocytoma metabolism, Pheochromocytoma pathology, Survival Analysis, Treatment Outcome, 3-Iodobenzylguanidine adverse effects, 3-Iodobenzylguanidine therapeutic use, Adrenal Gland Neoplasms radiotherapy, Paraganglioma radiotherapy, Pheochromocytoma radiotherapy, Safety
- Abstract
Patients with metastatic or unresectable (advanced) pheochromocytoma and paraganglioma (PPGL) have poor prognoses and few treatment options. This multicenter, phase 2 trial evaluated the efficacy and safety of high-specific-activity
131 I-meta-iodobenzylguanidine (HSA131 I-MIBG) in patients with advanced PPGL. Methods: In this open-label, single-arm study, 81 PPGL patients were screened for enrollment, and 74 received a treatment-planning dose of HSA131 I-MIBG. Of these patients, 68 received at least 1 therapeutic dose (∼18.5 GBq) of HSA131 I-MIBG intravenously. The primary endpoint was the proportion of patients with at least a 50% reduction in baseline antihypertensive medication use lasting at least 6 mo. Secondary endpoints included objective tumor response as assessed by Response Evaluation Criteria in Solid Tumors version 1.0, biochemical tumor marker response, overall survival, and safety. Results: Of the 68 patients who received at least 1 therapeutic dose of HSA131 I-MIBG, 17 (25%; 95% confidence interval, 16%-37%) had a durable reduction in baseline antihypertensive medication use. Among 64 patients with evaluable disease, 59 (92%) had a partial response or stable disease as the best objective response within 12 mo. Decreases in elevated (≥1.5 times the upper limit of normal at baseline) serum chromogranin levels were observed, with confirmed complete and partial responses 12 mo after treatment in 19 of 28 patients (68%). The median overall survival was 36.7 mo (95% confidence interval, 29.9-49.1 mo). The most common treatment-emergent adverse events were nausea, myelosuppression, and fatigue. No patients had drug-related acute hypertensive events during or after the administration of HSA131 I-MIBG. Conclusion: HSA131 I-MIBG offers multiple benefits, including sustained blood pressure control and tumor response in PPGL patients., (© 2019 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2019
- Full Text
- View/download PDF
33. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
- Author
-
Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schöder H, Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnston N, Leonard JP, Friedberg JW, Kahl BS, Cheson BD, and Bartlett NL
- Subjects
- Adolescent, Adult, Bleomycin administration & dosage, Cyclophosphamide administration & dosage, Dacarbazine administration & dosage, Disease-Free Survival, Doxorubicin administration & dosage, Etoposide administration & dosage, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Prednisone administration & dosage, Procarbazine administration & dosage, Survival Rate, Vinblastine administration & dosage, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Hodgkin Disease diagnostic imaging, Hodgkin Disease drug therapy, Hodgkin Disease mortality, Positron Emission Tomography Computed Tomography
- Abstract
A negative interim positron emission tomography/computerized tomography (PET/CT) after 1 to 3 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients with newly diagnosed, nonbulky stage I or II Hodgkin lymphoma (HL) predicts a low relapse rate. This phase 2 trial was designed to determine if a population of patients with early-stage disease can be treated with short-course ABVD without radiation therapy (RT) on the basis of a negative interim PET/CT, thereby limiting the risks of treatment. Between 15 May 2010 and 21 February 2013, 164 previously untreated patients with nonbulky stage I/II HL were enrolled, and 149 were included in the final analysis. Patients received 2 cycles of ABVD followed by PET. Deauville scores 1 to 3 were negative (≤ liver uptake) based on central review. PET
- patients received 2 more cycles of ABVD, and PET+ patients received 2 cycles of dose-intense bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (escalated BEACOPP) plus 3060-cGy involved-field RT. The primary objective was to determine 3-year progression-free survival (PFS) for the PET- group. One hundred thirty-five patients (91%) were interim PET- , and 14 patients (9%) were PET+ With median follow-up time of 3.8 years, the estimated 3-year PFS was 91% for the PET- group and 66% for the PET+ group (hazard ratio, 3.84; 95% confidence interval, 1.50-9.84; P = .011). There was 1 death as a result of suicide. Four cycles of ABVD resulted in durable remissions for a majority of patients with early-stage nonbulky HL and a negative interim PET. This trial was registered at www.clinicaltrials.gov as #NCT01132807., (© 2018 by The American Society of Hematology.)- Published
- 2018
- Full Text
- View/download PDF
34. Comparison of PET/CT and PET/MR imaging and dosimetry of yttrium-90 ( 90 Y) in patients with unresectable hepatic tumors who have received intra-arterial radioembolization therapy with 90 Y microspheres.
- Author
-
Knešaurek K, Tuli A, Kim E, Heiba S, and Kostakoglu L
- Abstract
Background: The aim of our study was to compare
90 Y dosimetry obtained from PET/MRI versus PET/CT post-therapy imaging among patients with primary or metastatic hepatic tumors. First, a water-filled Jaszczak phantom containing fillable sphere with90 Y-chloride was acquired on both the PET/CT and PET/MRI systems, in order to check the cross-calibration of the modalities. Following selective internal radiation therapy (SIRT) with90 Y microspheres, 32 patients were imaged on a PET/CT system, immediately followed by a PET/MRI study. Reconstructed images were transferred to a common platform and used to calculate90 Y dosimetry. A Passing-Bablok regression scatter diagram and the Bland and Altman method were used to analyze the difference between the dosimetry values., Results: The phantom study showed that both modalities were calibrated with less than 1% error. The mean liver doses for the 32 subjects calculated from PET/CT and PET/MRI were 51.6 ± 24.7 Gy and 46.5 ± 22.7 Gy, respectively, with a mean difference of 5.1 ± 5.0 Gy. The repeatability coefficient was 9.0 (18.5% of the mean). The Spearman rank correlation coefficient was very high, ρ = 0.97. Although the maximum dose to the liver can be significantly different (up to 40%), mean liver doses from each modalities were relatively close, with a difference of 18.5% or less., Conclusions: The two main contributors to the difference in90 Y dosimetry calculations using PET/CT versus PET/MRI can be attributed to the differences in regions of interest (ROIs) and differences attributed to attenuation correction. Due to the superior soft-tissue contrast of MRI, liver contours are usually better seen than in CT images. However, PET/CT provides better quantification of PET images, due to better attenuation correction. In spite of these differences, our results demonstrate that the dosimetry values obtained from PET/MRI and PET/CT in post-therapy90 Y studies were similar.- Published
- 2018
- Full Text
- View/download PDF
35. ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy.
- Author
-
Ratai EM, Zhang Z, Fink J, Muzi M, Hanna L, Greco E, Richards T, Kim D, Andronesi OC, Mintz A, Kostakoglu L, Prah M, Ellingson B, Schmainda K, Sorensen G, Barboriak D, Mankoff D, and Gerstner ER
- Subjects
- Aged, Brain diagnostic imaging, Brain metabolism, Brain Neoplasms metabolism, Brain Neoplasms mortality, Brain Neoplasms therapy, Female, Glioblastoma metabolism, Glioblastoma mortality, Glioblastoma therapy, Humans, Imaging, Three-Dimensional, Magnetic Resonance Imaging, Male, Middle Aged, Misonidazole analogs & derivatives, Positron-Emission Tomography, Prognosis, ROC Curve, Radiopharmaceuticals, Brain Neoplasms diagnostic imaging, Glioblastoma diagnostic imaging, Proton Magnetic Resonance Spectroscopy, Tumor Hypoxia physiology
- Abstract
A multi-center imaging trial by the American College of Radiology Imaging Network (ACRIN) "A Multicenter, phase II assessment of tumor hypoxia in glioblastoma using 18F Fluoromisonidazole (FMISO) with PET and MRI (ACRIN 6684)", was conducted to assess hypoxia in patients with glioblastoma (GBM). The aims of this study were to support the role of proton magnetic resonance spectroscopic imaging (1H MRSI) as a prognostic marker for brain tumor patients in multi-center clinical trials. Seventeen participants from four sites had analyzable 3D MRSI datasets acquired on Philips, GE or Siemens scanners at either 1.5T or 3T. MRSI data were analyzed using LCModel to quantify metabolites N-acetylaspartate (NAA), creatine (Cr), choline (Cho), and lactate (Lac). Receiver operating characteristic curves for NAA/Cho, Cho/Cr, lactate/Cr, and lactate/NAA were constructed for overall survival at 1-year (OS-1) and 6-month progression free survival (PFS-6). The OS-1 for the 17 evaluable patients was 59% (10/17). Receiver operating characteristic analyses found the NAA/Cho in tumor (AUC = 0.83, 95% CI: 0.61 to 1.00) and in peritumoral regions (AUC = 0.95, 95% CI 0.85 to 1.00) were predictive for survival at 1 year. PFS-6 was 65% (11/17). Neither NAA/Cho nor Cho/Cr was effective in predicting 6-month progression free survival. Lac/Cr in tumor was a significant negative predictor of PFS-6, indicating that higher lactate/Cr levels are associated with poorer outcome. (AUC = 0.79, 95% CI: 0.54 to 1.00). In conclusion, despite the small sample size in the setting of a multi-center trial comprising different vendors, field strengths, and varying levels of expertise at data acquisition, MRS markers NAA/Cho, Lac/Cr and Lac/NAA predicted overall survival at 1 year and 6-month progression free survival. This study validates that MRSI may be useful in evaluating the prognosis in glioblastoma and should be considered for incorporating into multi-center clinical trials., Competing Interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: Dr. Sorensen has been an employee of Siemens Medical Solutions from 2011-2016, and is currently a board member of IMRIS (includes equity stake). He also has two patents assigned to MGH (US patent # 8,698,496 and US patent # 7,512,435). Dr. Andronesi has one patent (US patent #8,698,496). Dr. Schmainda has an ownership interest in Imaging Biometrics LLC. Dr. Barboriak is a member of the GE Medical systems Neuro MRI Advisory Committee. Dr. Mankoff is an advisory for GE Healthcare. Dr. Ratai is a member on the advisory board for BrainSpec, Inc. Erin Greco is currently employed at Novartis Institutes for BioMedical Research, Cambridge, MA, United States. All other authors declare no conflicts of interest. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
- Published
- 2018
- Full Text
- View/download PDF
36. Surveillance Imaging in HPV-related Oropharyngeal Cancer.
- Author
-
Su W, Miles BA, Posner M, Som P, Kostakoglu L, Gupta V, and Bakst RL
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Oropharyngeal Neoplasms complications, Papillomaviridae physiology, Papillomavirus Infections complications, Papillomavirus Infections virology, Retrospective Studies, Treatment Outcome, Oropharyngeal Neoplasms diagnostic imaging, Oropharyngeal Neoplasms therapy, Positron Emission Tomography Computed Tomography methods, Salvage Therapy methods
- Abstract
Background/aim: Current guidelines derived from a pre-human papilloma virus (HPV) era in oropharyngeal cancer do not recommend routine surveillance imaging. We aimed to analyze the method of recurrence detection in HPV+ disease to determine a role for follow-up imaging., Patients and Methods: All HPV+ and HPV- oropharyngeal cancer patients treated at our institution from 2005-2016 with biopsy-proven recurrence were identified and their method of recurrence detection was analyzed., Results: A total of 16 HPV+ oropharyngeal cancer patients were identified to have recurrence, 12 (75%) of which experienced distant recurrence and 13 (81.3%) were detected asymptomatically with imaging at a median time of 19.7 months after initial treatment and verifying no residual disease. Twelve (75%) detections were with PET-CT. While HPV- patients (17 patients) also have a high rate of asymptomatic detection (16 patients, 94.1%), their 3-year post-recurrence survival was significantly lower at 6.5% compared to 83.6% for the HPV+ group (p<0.01)., Conclusion: In HPV+ patients, a large proportion of failures are asymptomatic distant metastases, which occur beyond 6 months following treatment completion, and are detected with whole body imaging alone. In light of long term post-recurrence survival observed, this preliminary data suggests that routine surveillance imaging should be further studied for HPV+ disease., (Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
37. Comparison of Standardized Uptake Value Ratio Calculations in Amyloid Positron Emission Tomography Brain Imaging.
- Author
-
Knešaurek K, Warnock G, Kostakoglu L, and Burger C
- Abstract
Amyloid positron emission tomography (PET) imaging with florbetapir
18 F (18 F-AV-45) allows in vivo assessment of cerebral amyloid load and can be used in the evaluation of progression of Alzheimer's disease (AD) and other dementias associated with b-amyloid. However, cortical amyloid deposition can occur in healthy cases, as well as in patients with AD and quantification of cortical amyloid burden can improve the18 F-AV-45 PET imaging evaluations. The quantification is mostly performed by cortical-to-cerebellum standardized uptake value ratio (SUVr). The aim of our study was to compare two methods for SUVr calculations in amyloid florbetapir18 F PET brain imaging. In amyloid florbetapir18 F PET brain imaging study, we imaged 42 cases with the mean age of 72.6 ± 9.9 (mean ± standard deviation). They were imaged on different PET/computed tomography systems with 369.0 ± 34.2 kBq of18 F florbetapir. Data were reconstructed using the vendor's reconstruction software. Corresponding magnetic resonance imaging (MRI) data were retrieved, and matched PET and MRI data were transferred to a common platform. Two methods were used for the calculation of the ratio of cortical-to-cerebellar signal (SUVr). One method was based on the MIM Software Inc., Version 6.4 software and only uses PET data. The second approach used the PMOD Neuro tool (version 3.5). This approach utilizes PET and corresponding MRI data (preferably T1-weighted) for better brain segmentation. For all the 42 cases, the average SUVr values for MIM and PMOD applications were 1.24 ± 0.26 and 1.22 ± 0.25, respectively, with a mean difference of 0.02 ± 0.15. The repeatability coefficient was 0.15 (12.3% of the mean). The Spearman's rank correlation coefficient was very high, r = 0.96. For amyloid-negative cases, the average SUVr values were lower than all group SUVr average values, 0.96 ± 0.07 and 1.00 ± 0.09, for MIM and PMOD applications, respectively. A mean difference was 0.04 ± 0.12, the repeatability coefficient was 0.12 (12.9% of the mean) and the Spearman's rank correlation coefficient was modest, r = 0.55. For amyloid-positive patients, the average SUVr values were higher than the same all group values, 1.34 ± 0.16 and 1.35 ± 0.20, respectively, with a mean difference of 0.01 ± 0.16. The repeatability coefficient was 0.16 (11.9% of the mean). The Spearman's rank correlation coefficient was high, r = 0.93. Our results indicated that the SUVr values derived using MIM and PMOD Neuro are effectively interchangeable and well correlated. However, PET template-based quantification (MIM approach) is clinically friendlier and easier to use. MRI template-based quantification (PMOD Neuro) better delineates different regions of the brain, can be used with any tracer, and therefore is more suitable for research., Competing Interests: There are no conflicts of interest.- Published
- 2018
- Full Text
- View/download PDF
38. Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using 18 F-Fluciclovine PET/CT.
- Author
-
Miller MP, Kostakoglu L, Pryma D, Yu JQ, Chau A, Perlman E, Clarke B, Rosen D, and Ward P
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Neoplasm Staging, Observer Variation, Prostatic Neoplasms metabolism, Recurrence, Carboxylic Acids, Cyclobutanes, Image Interpretation, Computer-Assisted methods, Positron Emission Tomography Computed Tomography, Prostatic Neoplasms diagnostic imaging, Prostatic Neoplasms pathology
- Abstract
18 F-Fluciclovine is a novel PET/CT tracer. This blinded image evaluation (BIE) sought to demonstrate that, after limited training, readers naïve to18 F-fluciclovine could interpret18 F-fluciclovine images from subjects with biochemically recurrent prostate cancer with acceptable diagnostic performance and reproducibility. The primary objectives were to establish individual readers' diagnostic performance and the overall interpretation (2/3 reader concordance) compared with standard-of-truth data (histopathology or clinical follow-up) and to evaluate interreader reproducibility. Secondary objectives included comparison to the expert reader and assessment of intrareader reproducibility. Methods:18 F-Fluciclovine PET/CT images ( n = 121) and corresponding standard-of-truth data were collected from 110 subjects at Emory University using a single-time-point static acquisition starting 5 min after injection of approximately 370 MBq of18 F-fluciclovine. Three readers were trained using standardized interpretation methodology and subsequently evaluated the images in a blinded manner. Analyses were conducted at the lesion, region (prostate, including bed and seminal vesicle, or extraprostatic, including all lymph nodes, bone, or soft-tissue metastasis), and subject level. Results: Lesion-level overall positive predictive value was 70.5%. The readers' positive predictive value and negative predictive value were broadly consistent with each other and with the onsite read. Sensitivity was highest for readers 1 and 2 (68.5% and 63.9%, respectively) whereas specificity was highest for reader 3 (83.6%). Overall, prostate-level sensitivity was high (91.4%), but specificity was moderate (48.7%). Interreader agreement was 94.7%, 74.4%, and 70.3% for the lesion, prostate, and extraprostatic levels, respectively, with associated Fleiss' κ-values of 0.54, 0.50, and 0.57. Intrareader agreement was 97.8%, 96.9%, and 99.1% at the lesion level; 100%, 100%, and 91.7% in the prostate region; and 83.3%, 75.0%, and 83.3% in the extraprostatic region for readers 1, 2, and 3, respectively. Concordance between the BIE and the onsite reader exceeded 75% for each reader at the lesion, region, and subject levels. Conclusion: Specific training in the use of standardized interpretation methodology for assessment of18 F-fluciclovine PET/CT images enables naïve readers to achieve acceptable diagnostic performance and reproducibility when staging recurrent prostate cancer., (© 2017 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2017
- Full Text
- View/download PDF
39. Reply: Fact Sheet About Interim and End-of-Treatment 18 F-FDG PET/CT in Lymphoma.
- Author
-
Kostakoglu L
- Subjects
- Humans, Lymphoma, Positron-Emission Tomography, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography
- Published
- 2017
- Full Text
- View/download PDF
40. Metabolic Tumor Volume: We Still Need a Platinum-Standard Metric.
- Author
-
Gallamini A and Kostakoglu L
- Subjects
- Antineoplastic Agents, Disease-Free Survival, Fluorodeoxyglucose F18, Platinum, Tumor Burden
- Published
- 2017
- Full Text
- View/download PDF
41. Response Assessment Criteria and Their Applications in Lymphoma: Part 2.
- Author
-
Moghbel MC, Mittra E, Gallamini A, Niederkohr R, Chen DL, Zukotynski K, Nadel H, and Kostakoglu L
- Subjects
- Algorithms, Humans, Reproducibility of Results, Sensitivity and Specificity, Decision Support Systems, Clinical, Image Interpretation, Computer-Assisted methods, Lymphoma diagnostic imaging, Lymphoma therapy, Outcome Assessment, Health Care methods, Positron Emission Tomography Computed Tomography methods
- Abstract
Interim and end-of-treatment PET/CT have become central to the evaluation of Hodgkin and non-Hodgkin lymphoma. This review article seeks to aid clinical decision making by providing an overview of available data on the diagnostic and prognostic value of PET/CT imaging for response assessment and pretransplant evaluation in lymphoma. The relative strengths and limitations of these techniques in various disease subtypes and clinical scenarios are explored, along with their current standards for reporting and latest developments. Particular attention is given to response-adapted therapy, which is emerging as a cornerstone of clinical management., (© 2017 by the Society of Nuclear Medicine and Molecular Imaging.)
- Published
- 2017
- Full Text
- View/download PDF
42. General Biomarker Recommendations for Lymphoma.
- Author
-
Rimsza L, Fedoriw Y, Staudt LM, Melnick A, Gascoyne R, Crump M, Baizer L, Fu K, Hsi E, Chan JW, McShane L, Leonard JP, Kahl BS, Little RF, Friedberg JW, and Kostakoglu L
- Subjects
- Clinical Trials as Topic, Congresses as Topic, Humans, Image Interpretation, Computer-Assisted, Lymphoma blood, Lymphoma diagnostic imaging, Positron Emission Tomography Computed Tomography, Prognosis, Biomarkers, Tumor blood, DNA, Neoplasm, Lymphoma pathology, RNA, Neoplasm, Research Design, Specimen Handling standards
- Abstract
Lymphoid malignancies are a heterogeneous group of tumors that have distinctive clinical and biological behaviors. The increasing prevalence of disease reflects both treatment advances and the fact that some of these tumors are indolent. The ability to determine treatment needs at diagnosis remains problematic for some of the tumors, such as in follicular lymphomas. Major clinical advances will likely depend on precision oncology that will enable identification of specific disease entities, prognostic determination at diagnosis, and identification of precise therapeutic targets and essential pathways. However, refinement in diagnostic evaluation is an evolving science. The ability to determine prognosis at diagnosis is variable, and for many of the lymphoid malignancies prognosis can only be made after initial treatment. Clinical trials that aim to evaluate specific features of these diseases are required in order to advance clinical practice that meaningfully addresses this important public health challenge. Herein, we describe the process and general recommendation from the National Cancer Institute (NCI) clinical trials planning meeting in November 2014 to address clinical trial design and biomarker proposals in the context of NCI-supported lymphoma clinical trials in the National Clinical Trials Network., (Published by Oxford University Press 2016. This work is written by US Government employees and is in the public domain in the US.)
- Published
- 2016
- Full Text
- View/download PDF
43. ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI.
- Author
-
Gerstner ER, Zhang Z, Fink JR, Muzi M, Hanna L, Greco E, Prah M, Schmainda KM, Mintz A, Kostakoglu L, Eikman EA, Ellingson BM, Ratai EM, Sorensen AG, Barboriak DP, and Mankoff DA
- Subjects
- Adult, Aged, Biomarkers analysis, Brain Neoplasms pathology, Disease-Free Survival, Female, Glioblastoma pathology, Humans, Male, Middle Aged, Misonidazole analogs & derivatives, Misonidazole pharmacology, Prospective Studies, Radiopharmaceuticals pharmacology, Brain Neoplasms blood supply, Brain Neoplasms mortality, Glioblastoma blood supply, Glioblastoma mortality, Magnetic Resonance Imaging, Neovascularization, Pathologic pathology, Positron-Emission Tomography, Tumor Hypoxia physiology
- Abstract
Purpose: Structural and functional alterations in tumor vasculature are thought to contribute to tumor hypoxia which is a primary driver of malignancy through its negative impact on the efficacy of radiation, immune surveillance, apoptosis, genomic stability, and accelerated angiogenesis. We performed a prospective, multicenter study to test the hypothesis that abnormal tumor vasculature and hypoxia, as measured with MRI and PET, will negatively impact survival in patients with newly diagnosed glioblastoma., Experimental Design: Prior to the start of chemoradiation, patients with glioblastoma underwent MRI scans that included dynamic contrast enhanced and dynamic susceptibility contrast perfusion sequences to quantitate tumor cerebral blood volume/flow (CBV/CBF) and vascular permeability (k
trans ) as well as18 F-Fluoromisonidazole (18 F-FMISO) PET to quantitate tumor hypoxia. ROC analysis and Cox regression models were used to determine the association of imaging variables with progression-free and overall survival., Results: Fifty patients were enrolled of which 42 had evaluable imaging data. Higher pretreatment18 F-FMISO SUVpeak (P = 0.048), mean ktrans (P = 0.024), and median ktrans (P = 0.045) were significantly associated with shorter overall survival. Higher pretreatment median ktrans (P = 0.021), normalized RCBV (P = 0.0096), and nCBF (P = 0.038) were significantly associated with shorter progression-free survival. SUVpeak [AUC = 0.75; 95% confidence interval (CI), 0.59-0.91], nRCBV (AUC = 0.72; 95% CI, 0.56-0.89), and nCBF (AUC = 0.72; 95% CI, 0.56-0.89) were predictive of survival at 1 year., Conclusions: Increased tumor perfusion, vascular volume, vascular permeability, and hypoxia are negative prognostic markers in newly diagnosed patients with gioblastoma, and these important physiologic markers can be measured safely and reliably using MRI and18 F-FMISO PET. Clin Cancer Res; 22(20); 5079-86. ©2016 AACR., Competing Interests: Dr. Sorensen reports stock ownership and employment with Siemens and patents/royalties/intellectual property with General Electric. Dr Schmainda reports ownership interest in Imaging Biometrics LLC. All other authors report no conflict of interest., (©2016 American Association for Cancer Research.)- Published
- 2016
- Full Text
- View/download PDF
44. Response Assessment Criteria and Their Applications in Lymphoma: Part 1.
- Author
-
Moghbel MC, Kostakoglu L, Zukotynski K, Chen DL, Nadel H, Niederkohr R, and Mittra E
- Subjects
- Humans, Treatment Outcome, Lymphoma therapy
- Abstract
The effectiveness of cancer therapy, both in individual patients and across populations, requires a systematic and reproducible method for evaluating response to treatment. Early efforts to meet this need resulted in the creation of numerous guidelines for quantifying posttherapy changes in disease extent, both anatomically and metabolically. Over the past few years, criteria for disease response classification have been developed for specific cancer histologies. To date, the spectrum of disease broadly referred to as lymphoma is perhaps the most common for which disease response classification is used. This review article provides an overview of the existing response assessment criteria for lymphoma and highlights their respective methodologies and validities. Concerns over the technical complexity and arbitrary thresholds of many of these criteria, which have impeded the long-standing endeavor of standardizing response assessment, are also discussed., (© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
45. The evolving role of response-adapted PET imaging in Hodgkin lymphoma.
- Author
-
Coyle M, Kostakoglu L, and Evens AM
- Abstract
(18)F-fluorodeoxyglucose positron emission tomography with (FDG-PET) has a well-established role in the pre- and post-treatment staging of Hodgkin lymphoma (HL), however its use as a predictive therapeutic tool via responded-adapted therapy continues to evolve. There have been a multitude of retrospective and noncontrolled clinical studies showing that early (or interim) FDG-PET is highly prognostic in HL, particularly in the advanced-stage setting. Response-adapted treatment approaches in HL are attempting to diminish toxicity for low-risk patients by minimizing therapy, and conversely, intensify treatment for high-risk patients. Results from phase III noninferiority studies in early-stage HL with negative interim FDG-PET that randomized patients to chemotherapy alone versus combined modality therapy showed a continued small improvement in progression-free survival for patients who did not receive radiation. Preliminary reports of data escalating therapy for positive interim FDG-PET in early-stage HL and for de-escalation of therapy [i.e. bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone (BEACOPP)] for negative interim FDG-PET in advanced stage HL (i.e. deletion of bleomycin) have demonstrated improved outcomes. Maturation of these studies and continued follow up of all response-adapted studies are needed. Altogether, the treatment of HL remains an individualized clinical management choice for physicians and patients. Continued refinement and optimization of FDG-PET is needed, including within the context of targeted therapeutic agents. In addition, a number of new and novel techniques of functional imaging, including metabolic tumor volume and tumor proliferation, are being explored in order to enhance staging, characterization, prognostication and ultimately patient outcome.
- Published
- 2016
- Full Text
- View/download PDF
46. A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.
- Author
-
Kostakoglu L, Duan F, Idowu MO, Jolles PR, Bear HD, Muzi M, Cormack J, Muzi JP, Pryma DA, Specht JM, Hovanessian-Larsen L, Miliziano J, Mallett S, Shields AF, and Mankoff DA
- Subjects
- Breast Neoplasms pathology, Female, Humans, Image Processing, Computer-Assisted, Ki-67 Antigen, Middle Aged, Positron-Emission Tomography, Predictive Value of Tests, Prospective Studies, ROC Curve, Treatment Outcome, Breast Neoplasms diagnostic imaging, Breast Neoplasms drug therapy, Dideoxynucleosides adverse effects, Neoadjuvant Therapy methods, Radiopharmaceuticals adverse effects
- Abstract
Unlabelled: Our objective was to determine whether early change in standardized uptake values (SUVs) of 3'deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) using PET with CT could predict pathologic complete response (pCR) of primary breast cancer to neoadjuvant chemotherapy (NAC). The key secondary objective was to correlate SUV with the proliferation marker Ki-67 at baseline and after NAC., Methods: This prospective, multicenter phase II study did not specify the therapeutic regimen, thus, NAC varied among centers. All evaluable patients underwent (18)F-FLT PET/CT at baseline (FLT1) and after 1 cycle of NAC (FLT2); 43 patients were imaged at FLT1, FLT2, and after NAC completion (FLT3). The percentage change in maximum SUV (%ΔSUVmax) between FLT1 and FLT2 and FLT3 was calculated for the primary tumors. The predictive value of ΔSUVmax for pCR was determined using receiver-operating-characteristic curve analysis. The correlation between SUVmax and Ki-67 was also assessed., Results: Fifty-one of 90 recruited patients (median age, 54 y; stage IIA-IIIC) met the eligibility criteria for the primary objective analysis, with an additional 22 patients totaling 73 patients for secondary analyses. A pCR in the primary breast cancer was achieved in 9 of 51 patients. NAC resulted in a significant reduction in %SUVmax (mean Δ, 39%; 95% confidence interval, 31-46). There was a marginal difference in %ΔSUVmax_FLT1-FLT2 between pCR and no-pCR patient groups (Wilcoxon 1-sided P = 0.050). The area under the curve for ΔSUVmax in the prediction of pCR was 0.68 (90% confidence interval, 0.50-0.83; Delong 1-sided P = 0.05), with slightly better predictive value for percentage mean SUV (P = 0.02) and similar prediction for peak SUV (P = 0.04). There was a weak correlation with pretherapy SUVmax and Ki-67 (r = 0.29, P = 0.04), but the correlation between SUVmax and Ki-67 after completion of NAC was stronger (r = 0.68, P < 0.0001)., Conclusion: (18)F-FLT PET imaging of breast cancer after 1 cycle of NAC weakly predicted pCR in the setting of variable NAC regimens. Posttherapy (18)F-FLT uptake correlated with Ki-67 on surgical specimens. These results suggest some efficacy of (18)F-FLT as an indicator of early therapeutic response of breast cancer to NAC and support future multicenter studies to test (18)F-FLT PET in a more uniformly treated patient population., (© 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
47. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
- Author
-
Evens AM and Kostakoglu L
- Subjects
- Humans, Prognosis, Reproducibility of Results, Tomography, X-Ray Computed, Fluorodeoxyglucose F18, Hodgkin Disease diagnostic imaging, Hodgkin Disease pathology, Positron-Emission Tomography
- Abstract
Given the excellent survival rates for early-stage Hodgkin lymphoma (HL), the young age of many patients, and concerns regarding acute and late treatment-related toxicities, there is a desire to have a predictive tool that enables therapy to be tailored toward the individual patient. Early (or interim) (18)F-fluorodeoxyglucose positron emission tomography with computerized tomography (FDG-PET/CT), as a test of tumor sensitivity to ongoing/planned therapy, has been shown to be prognostic for survival in HL. Based on results of interim FDG-PET/CT, therapy may be subsequently modified through minimization or via intensification for low- and high-risk patient populations, respectively (ie, response-adapted therapy). Important data have been generated to standardize the interpretability and reproducibility of interim FDG-PET/CT (eg, the Deauville 5-point system), and observational and noncontrolled prospective studies have produced evidence supporting the hypothesis that response-adapted therapy may potentially serve as a predictive tool. Furthermore, results from noninferiority phase 3 clinical trials randomizing early-stage HL patients with negative interim FDG-PET/CT to combined modality therapy versus chemotherapy alone have been reported. The current collective findings from these randomized early-stage HL studies have shown that acute relapse rates are lower with combined modality therapy, even in patients with negative interim FDG-PET/CT. Additional randomized response-adapted studies are ongoing and novel FDG-PET/CT applications involving quantitative techniques and innovative imaging modalities are being investigated to identify more robust imaging biomarkers. Treatment of early-stage HL remains a clinical management choice for physicians and patients to make with consideration of acute and long-term outcomes., (© 2014 by The American Society of Hematology. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
48. A consecutive case series experience with [18 F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition.
- Author
-
Mitsis EM, Bender HA, Kostakoglu L, Machac J, Martin J, Woehr JL, Sewell MC, Aloysi A, Goldstein MA, Li C, Sano M, and Gandy S
- Subjects
- Aged, Aged, 80 and over, Dementia diagnostic imaging, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Positron-Emission Tomography, Urban Population, Alzheimer Disease diagnostic imaging, Aniline Compounds, Decision Making, Ethylene Glycols, Quality of Life, Radiopharmaceuticals
- Abstract
Background: Identification and quantification of fibrillar amyloid in brain using positron emission tomography (PET) imaging and Amyvid™ ([18 F] Amyvid, [18 F] florbetapir, 18 F-AV-45) was recently approved by the US Food and Drug Administration as a clinical tool to estimate brain amyloid burden in patients being evaluated for cognitive impairment or dementia. Imaging with [18 F] florbetapir offers in vivo confirmation of the presence of cerebral amyloidosis and may increase the accuracy of the diagnosis and likely cause of cognitive impairment (CI) or dementia. Most importantly, amyloid imaging may improve certainty of etiology in situations where the differential diagnosis cannot be resolved on the basis of standard clinical and laboratory criteria., Results: A consecutive case series of 30 patients (age 50-89; 16 M/14 F) were clinically evaluated at a cognitive evaluation center of urban dementia center and referred for [18 F] florbetapir PET imaging as part of a comprehensive dementia workup. Evaluation included neurological examination and neuropsychological assessment by dementia experts. [18 F] florbetapir PET scans were read by trained nuclear medicine physicians using the qualitative binary approach. Scans were rated as either positive or negative for the presence of cerebral amyloidosis. In addition to a comprehensive dementia evaluation, post [18 F] florbetapir PET imaging results caused diagnoses to be changed in 10 patients and clarified in 9 patients. Four patients presenting with SCI were negative for amyloidosis. These results show that [18 F] florbetapir PET imaging added diagnostic clarification and discrimination in over half of the patients evaluated., Conclusions: Amyloid imaging provided novel and essential data that: (1) caused diagnosis to be revised; and/or (2) prevented the initiation of incorrect or suboptimal treatment; and/or (3) avoided inappropriate referral to an anti-amyloid clinical trial.
- Published
- 2014
- Full Text
- View/download PDF
49. FDG-PET imaging for Hodgkin lymphoma: current use and future applications.
- Author
-
Kostakoglu L and Evens AM
- Subjects
- Hodgkin Disease pathology, Hodgkin Disease therapy, Humans, Prognosis, Reproducibility of Results, Fluorodeoxyglucose F18, Hodgkin Disease diagnosis, Positron-Emission Tomography methods
- Abstract
A significant amount of data has been published over the past decade regarding the clinical utility of F-fluorodeoxyglucose positron emission tomography (FDG-PET) in the diagnosis and management of Hodgkin lymphoma (HL). This includes studies examining interim FDG-PET, which has been shown to be a strong tool for predicting relapse and survival, especially in advanced- stage HL. Despite progress, a number of questions remain regard- ing the precise role and value of FDG-PET in the diagnosis, risk stratification, and management of HL. These questions include the need for concomitant contrast enhanced computed tomography with FDG-PET, reproducibility and interpretability of FDG-PET, optimal imaging for the treatment surveillance of HL following definitive treatment, and the use of FDG-PET for patients with relapsed/refractory disease, including stem cell transplantation. In this review, these issues are critically examined and the study designs and results of observational and prospective FDG-PET response-adaptive clinical trials in HL are described in detail. In addition, novel techniques and future applications of FDG- PET, such as metabolic tumor volume, tumor proliferation via 3'-deoxy-3'-18F-fluorothymidine, and integrated PET/magnetic resonance imaging are discussed.
- Published
- 2014
50. State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response".
- Author
-
Kostakoglu L and Cheson BD
- Abstract
Lymphomas are heterogeneous but potentially curable group of neoplasms. Treatment of lymphomas has rapidly evolved overtime with significant improvement in the cure rate and reductions in treatment-related toxicities. Despite excellent results, treatment programs are continued to be developed to achieve better curative and safety profiles. In these patients individualized therapy schemes can be devised based on a well-defined risk categorization. The therapy efficacy can be increased early during therapy in non-responding patients with escalated therapy protocols or with the addition of radiation therapy, particularly, in advanced-stage or unfavorable risk patients. The increasing availability of positron emission tomography using 18F-fluorodeoxyglucose, particularly fused with computed tomography (FDG-PET/CT) has lead to the integration of this modality into the routine staging and restaging for lymphoma with convincing evidence that it is a more accurate imaging modality compared with conventional imaging techniques. FDG-PET/CT is also is a promising surrogate for tumor chemosensitivity early during therapy. This review will summarize published data on the utility of FDG-PET/CT imaging in the staging, restaging, and predicting therapy response in patients with lymphoma.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.